Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Although VYVGART still comprises the majority of prescriptions, we are seeing more traction with Hytrulo likely supported by access dynamics, favorable payer policies that mirror VYVGART and a dedicated J-Code in place |
| So, I think we're in a good position |
| So we're confident that we're bringing the innovation to the market that the patients really need |
| The key learnings and overlapping strategies between MG and CIDP give us more confidence in the long-term potential of VYVGART Hytrulo as a transformational treatment in CIDP |
| And we have over 4,000 patient years of safety follow-up with efgartigimod, which continues to support our consistent safety profile and with physicians this is a key differentiator |
| First and foremost, the launch trajectory demonstrates the significant unmet need that still exists with gMG and the opportunity for innovation like VYVGART to deliver differentiated outcomes for patients |
| We see consistent growth of our subscriber base having breadth and depth amongst neurologists and further reach into community centers |
| We continue to see double-digit quarter-over-quarter growth and we contribute this momentum to several factors, including a broader prescriber base, the continued shift to patients earlier in the treatment paradigm and additional regulatory approvals and launches in our ex-U.S |
| With over 6,000 patients on therapy, the response from the patient community has been tremendous and we've set the bar high for what a novel gMG treatment can offer |
| Importantly, this tells us that patients place a high value on innovative treatments such as VYVGART to meet the demand for safe and effective treatment alternatives in the gMG treatment space |
| We are energized by the incredible cadence of opportunities that remain ahead and we'll continue to approach the argenx way with relentless execution |
| We could have the most profound effect on the disease, but we also, of course, can leverage a very clean safety profile and a very competitive way of presenting the product |
| With a robust knowledge of FcRn and one of the most expansive sets of clinical and real world data generated to date, we are in a position of strength to continue to lead this market |
| Wrapping up on efgartigimod, I'm very proud of all that we have accomplished in pioneering this new class of medicines |
| At the core of everything we do is our mission to transform the lives of patients suffering from autoimmune diseases, and today, we are in a better position than ever to deliver on this mission, reaching more patients globally with our first-in-class innovation and bringing hope to the autoimmune community on what a novel treatment can offer |
| It has been an over year of incredible execution by the argenx team, setting us up to build on this momentum for the year ahead |
| has been strong with multiple launches and approvals already underway for 2024 |
| Karl Gubitz We had a really successful launch in Germany, and we of course had a really good price in Germany |
| I'm very proud of the team in Europe who has been working hard to secure reimbursement at a record pace in Germany, Italy, Spain and recently Belgium, with patients receiving access to VYVGART in half the average time historically needed by orphan drugs |
| So, we're very confident |
| And then and I think for us, from a VYVGART perspective, it just reinforces our leadership in the market |
| Second, IVIg is well entrenched and on label for CIDP patients |
| We had an incredible second year of launch, driven by the ambitious strategies and seamless execution of our commercial and medical teams |
| We're also seeing incredible uptake in China through our partnership with Zai Lab, driven by our recent inclusion on the NRDL |
| We laid out an ambitious plan for the year, and at two months in, we are already in a great position to deliver on our goals |
| We want to drive innovation beyond the molecule and on the patient experience in the form of new product presentation and a best in class support system |
| Karen Massey Absolutely, I'm really excited, for the prefilled syringe and the potential, to bring that to patients |
| The track record of success of our IIP goes well beyond efgartigimod and empa with nine programs tested in humans since inception |
| We're excited by the opportunity to expand our patient impact beyond MG this year with two upcoming regulatory decisions in ITP and CIDP |
| Echoing Tim, I'm thrilled with the impact this guide is having on patients and their loved ones |
| Statement |
|---|
| Most notably, there's an overall lack of innovation |
| But we also recognize there will be some unique challenges that may impact launch trajectory |
| I think the payer contracts, which will take a quarter or two to put in place, will definitely delay some of those revenues into 2025 |
| Net loss for the quarter was $99 million bringing the full year loss to $295 million |
| Secondly, I think the question number two relates to I think, review issue with the FDA |
| I know historically in Europe there is just naturally price deterioration |
| So, the same I think is valid for DM and it's not because of C5 blocker fails that upstream complement blocker defector would fail |
| There's been limited innovation, and these patients continue to progress, despite treatment, today |
| First on bullous pemphigoid, we’re just curious for the decision you're contemplating internally |
| As you said and as we shared in the prepared remarks, there's a few things that will impact the uptake this year |
| CIDP is a debilitating disease and one where patients continue to face significant burden, both from the symptoms of the disease, but also the demands of the available treatments |
| Tazeen Ahmad And then also a comment from your press release about price decrease in Germany |
Please consider a small donation if you think this website provides you with relevant information